My Cart

0 Item(s): $0.00

You have no items in your shopping cart.

Imatinib Mesylate

imatinib mesylate

Imatinib mesylate is a tyrosine kinase inhibitor and ANTINEOPLASTIC AGENT that inhibits the BCR-ABL kinase created by chromosome rearrangements in CHRONIC MYELOID LEUKEMIA and ACUTE LYMPHOBLASTIC LEUKEMIA, as well as PDG-derived tyrosine kinases that are overexpressed in gastrointestinal stromal tumors.

Imatinib Mesylate is the mesylate salt of imatinib, a tyrosine kinase inhibitor with antineoplastic activity. Imatinib binds to an intracellular pocket located within tyrosine kinases (TK), thereby inhibiting ATP binding and preventing phosphorylation and the subsequent activation of growth receptors and their downstream signal transduction pathways.

Drug type

Imatinib Mesylate is a targeted therapy. Imatinib Mesylate is classified as a signal transduction inhibitor - protein-tyrosine kinase inhibitor. (For more detail, see "How this drug works" below).

What Imatinib Mesylate Is Used For

Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.Ph+ CML in blast crisis, accelerated phase, or chronic phase after failure of interferon-alpha therapy.Adult patients with relapsed or refractory Philadelphia chromosome + acute lymphoblastic leukemia (Ph+ ALL).Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR gene rearrangements.Gastrointestinal stromal tumors that are C-kit positive.

How Imatinib Mesylate Is Given

Imatinib mesylate is a pill, taken by mouth, once or twice daily.

Imatinib mesylate should be taken with a large glass of water, after a meal.

The amount of Imatinib mesylate that you will receive depends on many factors, including your general health or other health problems, and the type of cancer or condition being treated.  Your doctor will determine your dose and schedule.

Side Effects

The following side effects are common (occurring in greater than 30%) for patients taking Imatinib mesylate:

Low blood counts.  Your white and red blood cells and platelets may temporarily decrease.  This can put you at increased risk for infection, anemia and/or bleeding.

  • Nausea and vomiting
  • Edema (swelling of the face, feet, hands)
  • Muscle cramps and bone pain
  • Diarrhea
  • Hemorrhage (see bleeding problems)
  • Skin rash (see skin reactions)
  • Fever
  • Headache
  • Fatigue
  • Joint pain
  • Indigestion (see heartburn)
  • Abdominal pain
  • Cough
  • Shortness of breath
  • Poor appetite
  • Constipation
  • Night sweats (see skin reactions)
  • Nose bleeds (see bleeding problems)
  • Weakness

Dosage

Missed Dose

Take the missed dose as soon as you remember. If it is almost time for the next scheduled dose, then the missed dose can be skipped. Contact your doctor for further instructions if you miss more than one scheduled dose of this medicine.

Overdose

Contact your doctor immediately if an overdose with this medicine is suspected. Symptoms may include nausea, vomiting, diarrhea, skin allergies, tiredness, fever, etc.

Warnings

Warnings for special population

Pregnancy - This medicine is not recommended for use in pregnant women unless absolutely necessary and the potential benefits outweigh the risks involved. Your doctor will determine the best course of treatment after assessing the clinical condition.

Breast-feeding - This medicine is not recommended for use in breastfeeding women unless absolutely necessary. Your doctor may advise you to discontinue breastfeeding or to discontinue the drug based on your clinical condition.

Know More About This Medicine and Buy Now : MedyPharma.com

Loading...